10-Hydroxycamptothecin

Research use only, not for human use.

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma. (In Vitro):(S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase.(S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells.(S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC50 of 1.15 μM.(In Vivo):(S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS).

(S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase.(S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells.(S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC50 of 1.15 μM. Cell Cycle Analysis Cell Line:Hep G2 cells Concentration:5 μg/L, 10 μg/L, 20 μg/L Incubation Time:6 days Result:Hep G2 cells were mainly arrested at G2/M phase.

(S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS).

ChEMBL 273862 | NSC 107124

Cell Cycle/DNA Damage

Topoisomerase

Topo I

Cancer

——

19685-09-7

364.36

C20H16N2O5

>98% (HPLC)

DMSO: 8 mg/mL warmed (21.95 mM)

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O

(S)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

(-20℃)

With Ice Pack

≥ 2 years